Note: Descriptions are shown in the official language in which they were submitted.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
1
DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN
BRAIN DISEASES
The present invention refers to selected galantamine derivatives having in
comparison to
galantamine higher efficacy and lower levels of adverse side effects in
treatment of human
brain diseases.
The plant alkaloid galantamine has been described as a cholinesterase
inhibitor (ChE-I)
and as a nicotinic acetylcholine receptor (nAChR) sensitizing agent (APL;
allosterically
potentiating ligand), and galantamine has been proposed for the treatment of
several
human brain diseases, including Alzheimer's disease (AD). Presently, the
compliance of
Alzheimer patients to treatment with ChE-I and APL is rather low, of the order
of 20%, a
key reason being the adverse effects nausea, diarrhea, vomiting, anorexia and
muscle
cramps. In the case of galantamine, the majority of these adverse effects is
due to actions
of the drug while passing through the gastro-intestinal tract, and to its
rather limited
permeation through the blood-brain barrier (BBB) into the brain. To help
patients coping
with the adverse effects of galantamine, the manufacturer's recommended daily
dose of
the drug is limited to 16-24 mg per day, and this dose is slowly reached by
stepwise dose
increase, beginning at 4 mg/day and over a period of 2-3 months.
The rather low levels of accumulation of galantamine in the brain, when
administered as
the unmodified drug, are a serious disadvantage with respect to the drug's
therapeutic use,
i.e. for the treatment of cognitive disorders, such as AD. As indicated by the
brain-to-
plasma ratio of 1.3, only a small part of the administered drug reaches the
brain, and the
high levels of the drug in other (peripheral) tissues cause most, if not all,
of the observed
adverse effects. The mostly peripheral action of galantamine is also indicated
in its
previous use for the treatment of a number of neuromuscular disorders,
including
Myasthenia gravis and poliomyelitis.
In W02007/039138 reference is made to the low hydrophobicity and related
limited
partition into the human brain of galantamine, and several procedures for
overcoming
these drawbacks of a medication that is supposed to act on target molecules
located in the
brain's central nervous system are proposed. In the same document numerous
derivatives
CONFIRMATION COPY
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
2
of galantamine that significantly improve transport of the respective compound
through
the blood-brain barrier (BBB) are described and they are proposed as drugs for
the
treatment of a variety of diseases associated with cognitive deficits.
EP-A 648 771, EP-A 649 846 and EP-A 653 427 all describe galantamine
derivatives, a
process for their preparation and their use as medicaments, however none of
these
applications considers ways and means of enhancing penetration through the
blood-brain
barrier and brain-to-plasma ratio of base compounds and derivatives.
US 6,150,354 refers to several galantamine analogues for the treatment of
Alzheimer's
disease. However, selective chemical modification for the purpose of
increasing
penetration through the blood-brain barrier is not considered.
WO 01/74820, WO 00/32199 and WO 2005030333 refer to derivatives and analogues
of
galantamine for the treatment of a variety of human brain and other diseases,
and acute
functional brain damage. However, selective chemical modifications or other
means of
improving blood-brain barrier penetration and brain-to-blood concentration
ratio are not
considered.
WO 88/08708, WO 99/21561, WO 01/43697 and US 2003/0162770 refer to derivatives
and analogues of galantamine for the treatment of various cognitive symptoms.
However,
selective chemical modifications or other means of improving brain-to-blood
concentration ratio are not considered.
WO 2005/030713 refers to a method for the synthesis of optical isomers of
galantamine
from a narwedine bromoamide derivative. However, it does not deal with other
derivatives
of galantamine, or their use as medicaments, or chemical modifications aimed
at
enhancing brain-to-blood concentration ratio of said compounds.
WO 97/40049 describes several derivatives of benzazepines and related
compounds that
may be applied for the treatment of Alzheimer's disease. However, no concept
is provided
CA 02721007 2012-08-16
WO 2009/127218 PCT/EP2008/002929
3
in this application for increasing the penetration of compounds through the
blood-brain
barrier and providing high brain-to-blood concentration ratio.
The object of the present invention is to provide compounds usable as pro-
drugs or as a
medicament having high pharmacodynamic effects in the brain's central nervous
system
and low peripheral side effects.
This object is met by compounds and compositions as provided herein.
The proposed derivatives were designed as pro-drugs, in the sense that they
are able to
effectively pass the blood brain barrier (BBB) and, after passing the BBB,
they are
substrates of endogenous enzymes and, upon enzymatic cleavage, produce
galantamine.
As a result of enzymatic cleavage to galantamine of such pro-galantamines in
the brain, a
significantly higher local concentration of galantamine is achieved in the
brain than by
administration of the same dose of original galantamine. The relatively higher
drug
concentration in the brain achieved by pro-galantamine administration will
then result in
higher efficacy at a given dose, and the better brain-to-peripheral tissues
distribution will
result in fewer or less significant side effects of treatment. These effects
are significant
improvements of present treatment regimens because the efficacy as treatment
for brain
diseases of unmodified galantamine (and all other ChE-I presently approved for
this
purpose) is rather limited, albeit statistically significant, possibly due to
low dosing. Thus,
efficacy is usually reached only after careful (months-long) up-titration of
daily dose, so as
to maintain sufficient compliance of patients to the largely gastro-intestinal
side effects
associated with ChE-I treatment.
According to the present invention it was found that careful selection
concerning the type
of substituent and the position of substitution using galantamine as base
structure result in
highly efficacious compounds. Such very efficacious compounds having good
blood
brain barrier passing properties and being efficiently cleaved by an esterase
after passage
through the BBB are obtained with compounds having the general formula I
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
4
0
0 R1
00
H3C 1401
CH3
with R1 being a substituent having particular sterical and hydrophobic
properties.
The present invention focuses on esters of galantamine that as such have
little or no
activity as ChE-I and APL compared to galantamine. Therefore, as long as these
compounds remain uncleaved, they do not interact with the usual target
molecules of
galantamine and hence are largely inactive in producing therapeutic and/or
side effects.
The reduced reactivity of pro-galantamines is demonstrated by the following
results:
I. Significantly reduced activity as ChE-I, as compared to galantamine.
2. Reduced activity as nicotinic APL, as compared to galantamine.
3. Reduced gastro-intestinal side effects, as compared to galantamine.
All these approaches were investigated and are explained in the examples and
shown in
the figures.
According to the invention it has been discovered that a particular group of
esters of
galantamine display unexpectedly high brain-to-blood concentration ratios (RBB-
proGal >
6, as compared to RBB-Gal ¨ 1.3) and in the brain they are relatively slowly
enzymatically
cleaved to galantamine. Therefore, as is discussed below in more detail, these
pro-
galantamines are exceptionally well suited for the treatment of human diseases
associated
with cholinergic deficits, such as Alzheimer's disease, Parkinson's disease,
Schizophrenia
and a variety of other psychiatric disorders.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
The esters of galantamine to which the present invention refers to have the
following
general structure:
0
0 R1
00
leH3C0
CH3
5 Formula I
wherein R1 either is CH(C2H5)CH3, CH2-C(CH3)3, or cyclopropane or being an
optionally
substituted aromatic or hetero-aromatic 5- or 6-membered ring. Specifically,
such
aromatic and hetero-aromatic rings include benzene, naphthalene, thiophene,
pyrrole,
imidazole, pyrazole, oxazole and thiazole, in case that they are used as
medicaments or
pro-drugs for the treatment of neurodegenerative or psychiatric or
neurological disease
associated with a cholinergic deficit.
Such a disease preferably is selected from Alzheimer's and Parkinson's
disease, other
types of dementia, schizophrenia, epilepsy, neuritis, various types of
poisoning,
anesthesia, particularly neuroleptic anesthesia, autism, spinal cord
disorders,
inflammation, particularly central inflammatory disorders, postoperative
delirium and/or
subsyndromal postoperative delirium, neuropathic pain, subsequences of the
abuse of
alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of
radiotherapy.
The above mentioned compounds were not yet described for the treatment of such
diseases. Furthermore, compounds of formula I having aromatic or hetero-
aromatic 5- or
6-membered ring, selected from substituted benzene with the proviso that it is
not 2-
fluorobenzene or 3-nitro-4-fluorobenzene, optionally substituted naphthalene,
thiophene,
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
6
PYrrole, imidazole, pyrazole, oxazole, thiazole; or CH(C2H5)CH3, CH2-C(CH3)3,
or
cyclopropane are according to the knowledge of the inventor not yet described
at all.
In one preferred embodiment the compounds of the present invention are
selected from
0 R2
0
1101 R3
0 R6 R4
0
H3C
R5
,0 40
N
\
CH3
Formula II
wherein R2-10 comprising any substituent selected from H, halogen, optionally
substituted C1-C3 alkyl or cyclopropyl, OH, 0-alkyl, SH, S-alkyl, NH2, NH-
alkyl, N-
dialkyl, optionally substituted aryl or hetero-aryl, whereby neighbouring
substitutents can
cooperate to form an additional ring.
In another preferred embodiment of the present invention the compounds are
selected
from the group consisting of the compounds as shown in table A, which is
attached below.
Herein the term "pro-drug" refers to a derivative of galantamine (base
compound) wherein
the group(s) added or replaced on said base compound are cleaved or returned
to the
hydroxyl group originally contained in the base compound, when the derivative
has
reached the area or site of action. Thus, in case of a "pro-drug", an
effective agent is
administrated as a derivative (which is said pro-drug), however, the compound
mainly or
exclusively effective at the target site within the brain is the agent itself,
not the
derivatised compound or metabolites other than the base compound thereof.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
7
The term "derivative" refers to any change of a base compound defined in the
present
application. The term "derivative" is used to describe a compound which either
can be a
pro-drug, or can be an effective agent itself/in its own right or in the
derivatised form.
The term "pro-galantamine" is used for any derivative of galantamine described
herein
which can be cleaved by an enzyme (esterase) resulting in galantamine.
The terms "sensitising agent" and "allosterically potentiating ligand, APL"
refer to
effectors that enhance cholinergic neurotransmission by interaction with an
allosteric site
at cholinergic receptors.
The terms "cholinergic enhancer" and "cholinergic agent" refer to compounds
that
enhance/modulate cholinergic neurotransmission by inhibition of
cholinesterases, by
allosteric sensitisation and/or direct activation of cholinergic receptors
and/or by
activating/modulating relevant intracellular pathways via second messenger
cascades.
A derivative or pro-drug has an "enhanced blood-brain barrier permeability
"according to
the present invention or an "enhanced blood-brain barrier penetration" if,
after
administration of a pro-drug or derivative thereof to a living organism, a
higher amount of
said compound penetrates through the BBB of that organism.
A compound of the present invention provides an increased "brain-to-blood
concentration
ratio" or "brain-to-tissue concentration ratio" resulting in a higher level of
effective agent
in the brain, as compared to administration of the base compound without
derivatisation.
Methods for determination of an enhanced BBB permeability are disclosed in WO
2007/039138.
The "base compound" as well as the "effective agent" according to the present
invention is
galantamine. The effective agent is obtained by (local) enzymatic cleavage of
the
derivative.
"logP" is defined as the decadic logarithm of the partition coefficient P
which is the ratio
of the concentration of a compound in aqueous phase to the concentration of a
compound
in immiscible solvent, as the neutral molecule.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
8
The term "alkyl" shall mean a straight, branched or cyclic alkyl group. As
"alkyl" C1 to
Clo alkyl groups are preferred, C2 to C8 groups are more preferred and C2 to
C6 groups are
most preferred. Ci to C10 means alkyl groups of the stated number of carbon
atoms.
Examples include, but are not limited to methyl, ethyl, n-propyl, iso-propyl,
n-butyl,
isobutyl, sec-butyl, t-butyl, and straight and branched chain pentyl, hexyl,
heptyl, octyl,
nonyl and decyl etc...or the according cyclic alkyls.
The term "halo" shall mean chloro, fluoro, bromo and iodo.
The term "aryl" shall mean phenyl having 0, 1, 2, 3, 4 or 5 substituents
independently
selected from the group of alkyl, alkoxy, alkylcarbonyl, halo- or
trihalomethyl.
The term "cycloalkyl" shall mean a cycloalkyl group of from 3 to 10 carbon
atoms and
including multiple ring alkyls such as for example, adamantyl, camphoryl, and
3-
noradamantyl.
In any case when a range between two limits is described it is meant that any
value or
integer in this range is disclosed. For example "C1-C10" means C1, C2, C3, C4,
C5, C6 ,C7,
C8. C9 or C10; or "between 0,1 and 1" means 0,1, 0,2, 0,3, 0,4, 0,5, 0,6, 0,7,
0,8, 0,9 or 1.
The stereo chemistry of the described derivatives are the same as that of
galantamine.
Benzoyl esters of galantamine were previously described in WO 9921561 Al
Davis,
Bonnie M. for a method of treatment of disorders of attention with
galanthamine,
lycoramine, and related compounds, but no syntheses or analytical or other
data were
provided for these compounds.
Substituted benzoyl esters were previously described in "Synthesis and
biological activity
of galanthamine derivatives as acetylcholinesterase (AChE) inhibitors" by Han,
So Yeop;
Mayer, Scott C.; Schweiger, Edwin J.; Davis, Bonnie M.; Joullie, Madeleine M.
Dep.
Chem., Univ. Pennsylvania, Philadelphia, PA, USA.
Bioorganic & Medicinal
Chemistry Letters (1991), 1(11), 579-80. CODEN: BMCLE8 ISSN: 0960-894X.
Journal written in English. CAN 116:83569 AN 1992:83569
CAPLUS. In this
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
9
document the synthesis of several ester and carbamate derivatives of
galanthamine are
described as well as it was suggested that these compounds are potential
therapeutic
agents in the treatment of Alzheimer's disease, based on their properties as
AChE
inhibitors.
In contrast to the teaching of these documents, the galantamine esters of the
present
invention have little, if any, activity as acetylcholinesterase inhibitors but
rather are
substrates of said enzyme (see above).
As representatively demonstrated for the benzoyl derivative in Figure 1, these
esters have
little, if any cholinesterase inhibitory activity but rather are hydrolysed by
cholinesterases
to form galantamine and accordingly act as pro-drugs of galantamine. As soon
as
galantamine is generated from these compounds, it acts as ChE-I and APL, as
has
previously been described. The structures of the tested derivatives can be
seen in table A.
As a comparative derivative a non-cleavable galantamine ether is also tested.
Such
derivative results in negative values of inhibition. In derivative Gln 1063 RI
in formula I
is ¨0-Si(CH3)2-C(CH3)2-C(CH3)2H=
Rather than inhibiting cholinesterases, the pro-galantamines referred to in
the present
document are substrates of the enzyme, as is exemplarily demonstrated in
Figure 2.
The data of figures I and 2 demonstrate that pro-galantamines of the present
invention do
not act as efficient inhibitors of cholinesterase, as was described in the
earlier documents
discussed above. Instead, they are substrates of these enzymes. Similarly,
they also do not
interact to the same extend as galantamine with neuronal nicotinic
acetylcholine receptors
(figure 3).
The pro-galantamines of the present invention therefore either do not
interact, or only to a
very limited extend, with the established target molecules of galantamine, in
particular
cholinesterases and neuronal nicotinic acetylcholine receptors. As pro-drugs
they therefore
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
have rather limited, if any, efficacy as cognition enhancers, and also produce
only limited
peripheral and central side effects, as compared to galantamine (see further
below).
As is exemplified and demonstrated by pharmacokinetics in mice (figures 4a and
4b, table
5 1), R1 -benzoyl-galantamine displays an unexpectedly high brain-to-blood
concentration
ratio (RBB-proGal > 19), a large initial concentration in the brain, and it is
only slowly
cleaved to galantamine, as seen in the delayed appearance of a galantamine
peak in brain
and blood. The RBB-value is significantly larger than what was expected from
the logP
value which probably is due to the slow cleavage of the pro-drug in the brain
and a depot
10 effect thereby produced.
In table 1, the key pharmacokinetic data of benzoyl-galantamine, of several
other R1 -pro-
galantamines and of galantamine (for comparison) are listed.
Table 1: Pharmacokinetic data of several Rl-pro-galantamines in the mouse
Gin number
(for reference
see table A) logP Co (Brain) R-Pro R-Gal
1062 3.0 4812 19.3 2.2
1067 2.8 4665 7.5 1.7
0979 2.5 3166 6.2 2.4
0993 3.7 2150 6.4 0.6
0978 2.2 1985 6.9 2.3
1076 2.4 1245 1.1 1.0
Gal 1.7 1741 1.2
Co is the highest pro-galantamine concentration (ne/m1) achieved in mouse
brain after i.v.
injection of 3 mg/kg of pro-galantamine. R-Pro 1st he brain-to-blood
concentration ratio of pro-
galantamine, R-Gal that of galantamine under these experimental conditions.
For comparison, Co
and R-Gal are also provided for i.v, injection of the same amount of
galantamine.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
11
These data establish that only a particular selection of RI substitutions is
capable of
producing the following advantageous properties of pro-galantamines; high
initial
concentration in the brain, large RBB, and slow enzymatic conversion to
galantamine. In
addition (not shown in the table), the preferred R1 -prodrugs display little,
if any side
effects, as they are only very slowly converted to galantamine, thereby
largely protecting
them from acting as galantamine while being transported from the site of
administration to
the sites of action in the brain.
These properties may have significant impact for the use of these compounds as
drugs in
Alzheimer's disease and other brain diseases. As is representatively shown in
figure 5, R1-
pro-galantamines of the present invention display in ferrets much less gastro-
intestinal
side effects than galantamine. Ferrets were used in these studies as they are
known to be
particularly sensitive to gastro-intestinal side effects. In addition to the
classical emetic
responses to galantamine and other ChE inhibitors, we recorded salivation
(SA), shivering
(SH), respiratory problems (RP) and diarrhea (DI) at the levels "none; 0",
"moderate; 0.5"
(behaviour observed at low frequency and/or at low intensity) and "intense;
1.0"
(behaviour observed frequently and/or continuously and/or at high intensity),
and
summated the scores for the four animals each used per drug dose in these
studies.
The data depicted in figure 5 for the two pro-galantamines demonstrate that
their side
effects profile in ferrets is much less severe (5-6 times less) than that of
the same dose of
galantamine. The advantageous side effects profile is probably due to the
reduced affinity
of interaction of these R1 -pro-galantamines with cholinesterases and neuronal
nicotinic
acetylcholine receptors (figures 1, 3).
The advantages of enhanced transport of selected R1 -produgs through the blood-
brain
barrier into the brain, enzymatic conversion to galantamine close to target
sites in the
central nervous system, and interaction with such sites is producing enhanced
reversal of
drug-induced amnesia in mice, as is shown in figure 6 for three pro-
glantamines (and for
galantamine in comparison).
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
12
The data of figure suggest that Gln-1062 is approximately 4-times more
efficacious than
galantamine in reversing scopolamine-induced amnesia in mice. It may be
expected that a
similar or larger increase in drug efficacy can be achieved in man when the
particular R1-
pro-galantamine is administered instead of galantamine. The advantageous drug
properties
of R1 -pro-galantamines (higher efficacy, lesser or less intense side effects)
were also
shown in other animal models.
In summary, the compounds of this invention are particularly useful as
medicaments for
the treatment of human brain diseases associated with a cholinergic deficit,
including the
neurodegenerative diseases Alzheimer's and Parkinson's disease and the
neurological/psychiatric diseases vascular dementia, schizophrenia and
epilepsy. Based on
preclinical studies using various animal models, the compounds have
dramatically reduced
side effects as compared to galantamine, including much fewer, if any,
incidents of emetic
responses, diarrhea and vomiting. Moreover, when enzymatically cleaved, the
resulting
galantamine displays an advantageous pharmacokinetic profile in the brain and,
due to its
enhanced concentration level in the brain, displays also enhanced efficacy in
interaction
with the target molecules located in the brain. Taken together, these
properties make the
administration of galantamine as a R1 -prodrug a preferred medication in the
diseases
mentioned above.
Figures
Figure 1: Brain esterase inhibition by galantamine and several pro-
galantamines.
A 20% mouse brain homogenate was used, supplemented with 200 M of
acetylthiocholine as substrate, and the initial reaction kinetics were
measured according to
Riddles PW, Blakeley RL, Zerner B., õReassessment of Ellman's reagent."
Methods
Enzymol. 1983;91:49-60. As shown in the figure, even 50 M of the respective
pro-
galantamines were unable to achieve a level of inhibition of brain
cholinesterase that is
comparable in size to that of 1 M galantamine. A non-cleavable galantamine
derivative
(Gln 1063) leads to negative values. In derivative Gln 1063 R1 in formula I is
¨0-
Si(CH3)2-C(CH3)2-C(CH3)2H.
Figure 2: Enzymatic cleavage of pro-galantamine to galantamine.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
13
Butyrylcholinesterase, 25 units/ml, was used. Reaction temperature was 37 C.
Appearance
of the fluorescent reaction product galantamine was determined by fluorescence
detection.
Figure 3: Interaction of galantamine and pro-galantamine with a4I32 neuronal
nicotinic
The increase in response to acetylcholine in the presence of galantamine and
Gln-1062,
respectively, was determined by whole-cell patch clamp recording. Galantamine
achieved
a maximal enhancement of response of ¨ 40% whereas the pro-galantamine
achieved a
maximal enhancement of only ¨ 17%.
Figure 4: Pharmacokinetics of pro-galantamine Gln-1062 (3mg/kg) in the mouse
Figure 4a shows the measurable concentration of applied pro-galantamine and
the
resulting concentration of galantamine by cleavage of the pro-galantamine in
brain and
brain. The curve starting with the highest concentration refers to derivative
GLN-1062,
Figure 5: Behavioural index for gastro-intestinal side effects in ferrets
following
application of galantamine and several Rl-pro-galantamines, respectively.
25 Figure 6: Reversal from scopolamine-induced amnesia in mice, in the
presence of
galantamine and several RI -pro-galantamines, respectively.
Scopolamine induces a memory deficit that can be measured by increased
alternation in a
T-maze trial. The cognition enhancing drugs were i.p. injected at several
different doses
together with scopolamine 20 min before a T-maze trial. Recovery was measured
as a
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
14
=
Examples
Examples of chemical synthesis and chemical properties of derivatives:
Abbreviations: DCM: dichloromethane; DMAP: 4-dimethylaminopyridine, DCC:
dicyclohexylcarbodiimide; DCHU: dicyclohexylurea
General procedure 1
To the solution of (-)-galanthamine hydrobromide (1.0 mole) and triethyl amine
(4.0 mol)
in DCM (30 mL), DMAP (0.5 mol) was added followed by respective acid chloride
or
acid anhydride (1.2 mol). The mixture was stirred overnight at room
temperature under
argon. The reaction mixture was washed with 10% NaHCO3 and brine, dried
(Na2SO4)
and concentrated. The crude compound obtained was purified by column
chromatography
or recrystallization to give the pure product.
0
=A R
OH
,s1H AoH
0 0 0 RA Et3N/CH2Cl2
0
CI RAO AR 0
0 ,õ)
DMAP
NHBr
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
=
= ==
"41 111 CI
H "41 .0H = .µ,H
CI A& Hlok
CI
0 0 W
0 ===õ)
0 ===õ) 0 .... 0 ',õ)
Using this procedure the following compounds were obtained:
5 Example 1: 0-Benzoyl-galanthamine (=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-
methoxy-11-methy1-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, benzoate
(ester)); yield:
78%
Example 2: 0-3 ,4-Dichlorobenzoyl-galanthamine (¨(4aS,6R,8aS)-4a,5,9,10,11,12-
10 Hexahydro-3-methoxy-11 -methyl-6H-benzofuro [3 a,3 ,2-ef] [2]benzazepin-
6-ol, 3,4-
dichlorobenzoate (ester)); off-white solid; mp. 69-70 C.
1H NMR ( 200 MHz, CDC13 ) 8 (ppm) 8.02 (d, J= 1.88 Hz, 1H), 7.81 (dd, J= 1.88
Hz,
J= 8.38 Hz, 1H), 7.38 (d, J = 8.32 Hz, 1H), 6.62 (d, J = 8.18 Hz, 1H), 6.52
(d, J = 8.18
15 Hz, 1H), 6.32 (d, J= 10.34 Hz, 1H), 5.89-5.97 (m, 1H), 5.51 (t, J= 4.43
Hz, 1H), 4.58 (s,
1H), 4.07 (d, J= 15.16 Hz, 1H), 3.18 (s, 3H), 3.61 (d, J= 15.16 Hz, 1H), 3.21-
3.45 (m,
1H), 2.96-3.05 (m, 1H), 2.66-2.76 (m, 1H), 2.34 (s, 3H), 2.0-2.19 (m, 2H),
1.51-1.59 (m,
1H).
Example 3: 0-4-Methoxybenzoyl-galanthamine (=(4aS,6R,8aS)-4a,5,9,10,11,12-
Hexahydro-3-methoxy-11-methy1-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol,
4-
methoxybenzoate (ester)); off-white solid; mp. 183-184 C.
1H NMR ( 200 MHz, CDC13 ) 6 (ppm) 8.01 (d, J = 9.0 Hz, 2H), 8.56 (d, J = 8.86
Hz,
2H), 6.69 (d, J = 8.18 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.35 (d, J = 10.2
Hz, 1H), 6.0-
6.07 (m, 1H), 5.56 (t, J= 4.49 Hz, 1H), 4.66 (s, 1H), 4.15 (d, J¨ 15.18 Hz,
1H), 3.89 (s,
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
16
3H), 3.84 (s, 3H), 3.68 (d, J= 15.18 Hz, 1H), 3.29-3.53 (m, 1H), 3.04-3.12 (m,
1H), 2.73-
2.81 (m, 1H), 2.41 (s, 3H), 2.08-2.26 (m, 2H), 1.58-1.66 (m, 1H).
Example 4: 0-4-Methylbenzoyl-galanthamine (=(4aS,6R,8aS)-4a,5,9,10,11,12-
Hexahydro-3-methoxy-11-methy1-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4-
methylbenzoate (ester)); off-white solid; mp. 71-72 C.
1H NMR ( 200 MHz, CDC13 ) ö (ppm) 7.94 (d, J= 8.18 Hz, 2H), 7.17 (d, J= 8.06
Hz,
2H), 6.69 (d, J= 8.18 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.35 (d, J= 9.52 Hz,
1H), 6.0-
6.08 (m, 1H), 5.57 (t, J = 4.43 Hz, 1H), 4.66 (s, 1H), 4.17 (d, J= 15.18 Hz,
1H), 3.89 (s,
3H), 3.70 (d, J= 15.18 Hz, 1H), 3.31-3.43 (m, 1H), 3.06-3.13 (m, 1H), 2.74-
2.83 (m, 1H),
2.42 (s, 3H), 2.38 (s, 3H), 2.08-2.26 (m, 2H), 1.59-1.67 (m, 1H).
Example 5: 0-4-Chlorobenzoyl-galanthamine (=(4aS,6R,8aS)-4a,5,9,10,11,12-
Hexahydro-3-methoxy-11-methy1-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4-
chlorobenzoate (ester)); off-white solid; mp.72-74 C.
1H NMR ( 200 MHz, CDC13 ) ö (ppm) 7.91 (d, J= 8.74 Hz, 2H), 7.27 (d, J= 8.72
Hz,
2H), 6.62 (d, J= 8.2 Hz, 1H), 6.52 (d, J= 8.2 Hz, 1H), 6.30 (d, J= 10.34 Hz,
1H), 5.92-
6.0 (m, 1H), 5.5 (t, J= 4.36 Hz, 1H), 4.59 (s, 1H), 4.09 (d, J= 15.18 Hz, 1H),
3.82 (s, 3H),
3.63 (d, J= 15.18 Hz, 1H), 3.23-3.46 (m, 1H), 2.99-3.06 (m, 1H), 2.66-2.76 (m,
1H), 2.35
(s, 3H), 2.0-2.2 (m, 2H), 1.52-1.6 (m, 1H).
Example 6: 0-2-Thenoyl-galanthamine (=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-
methoxy-11-methy1-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, thiophene-2-
carboxylate
(ester)); off-white solid; mp.115-116 C.
1H NMR ( 200 MHz, CDC13 ) 5 (ppm) 7.78 (dd, J= 1.2 Hz, J = 3.8 Hz, 1H), 7.51
(dd, J
= 1.34 Hz, J = 4.96 Hz, 1H), 7.04 (dd, J= 3.76 Hz, J = 4.98 Hz, 1H), 6.69 (d,
J= 8.18 Hz,
1H), 6.59 (d, J= 8.04 Hz, 1H), 6.35 (d, J= 10.2 Hz, 1H), 6.02 (dd, J= 4.7 Hz,
J = 10.2
Hz, 1H), 5.54 (t, J= 4.49 Hz, 1H), 4.63 (s, 1H), 4.18 (d, J= 15.02 Hz, 1H),
3.87 (s, 3H),
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
17
3.71 (d, J= 15.18 Hz, 1H), 3.31-3.5 (m, 1H), 3.07-3.14 (m, 1H), 2.73-2.83 (m,
1H), 2.42
(s, 3H), 2.04-2.26 (m, 2H), 1.6-1.68 (m, 1H).
Example 7: 0-5-Chloro-2-thenoyl-galanthamine (=(4aS,6R,8aS)-4a,5,9,10,11,12-
Hexahydro-3-methoxy-11-methy1-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 5-
chlorothiophene-2-carboxylate (ester)); off-white solid; mp. 58-59 C.
1H NMR ( 200 MHz, CDC13 ) 8 (ppm) 7.5 (d, J= 4.04 Hz, 1H), 7.80 (d, J= 4.02
Hz,
1H), 6.62 (d, J= 8.04 Hz, 1H), 6.52 (d, J= 8.06 Hz, 1H), 6.31 (d, J= 10.2 Hz,
1H), 5.92
(dd, J= 4.57 Hz, J= 10.2 Hz, 1H), 5.45 (t, J= 4.36 Hz, 1H), 4.56 (s, 1H), 4.08
(d, J=
15.16 Hz, 1H), 3.81 (s, 3H), 3.61 (d, J= 15.18 Hz, 1H), 3.21-3.34 (m, 1H),
2.97-3.04 (m,
1H), 2.64-2.74 (m, 1H), 2.34 (s, 3H), 1.97-2.19 (m, 2H), 1.5-1.57 (m, 1H).
General procedure 2
To the solution of the corresponding acid acid (13.87 g, 135.8 mmol) in DCM
(250 mL )
was added DCC (33.62 g, 162.9 mmol) followed by DMAP (3.32 g, 27.15 mmol),
reaction mixture was stirred for additional 30 minutes at room temperature .To
this (-)-
galanthamine hydrobromide (10.0 g, 27.15 mmol) and triethyl amine (4.6 mL,
32.59
mmol) was added, the mixture was stirred overnight at room temperature under
argon. The
precipitated DCHU was removed by filtration and the filtrate was evaporated.
The
additional DCHU was removed by subsequent trituration with cold ethyl acetate
and
filtration. The ethyl acetate solution was roto-evaporated and the crude
product obtained
was purified by column chromatography to give the desired product.
Example 8:
2-Methyl-butanoyl-galanthamine (=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-
methoxy-
11-methy1-6H-benzofiiro[3a,3,2-ef][2]benzazepin-6-ol, 2-methyl-butanoate
(ester)) was
obtained in 53% yield as a solid using the general procedure 2.
The same product, identical in every respect (HPLC, m.p., 1H-NMR), was also
obtained
in 58% yield using the general procedure 1.
Example 9:
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
18
2-Methyl-propanoyl-galanthamine
(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-
methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol,
2-methyl-propanoate
(ester)) was obtained in 63% yield as a solid using the general procedure 1.
Example 10:
2-Methyl-propanoyl-galanthamine hydrochloride salt
To the solution of 2-methyl-propanoyl-galanthamine (150 mg, 0.43 mmol) in
ethyl acetate
(5 mL), ethyl acetate saturated with HC1 (5 mL) was added slowly with stirring
at 0 C.
The reaction mixture was stirred at room temperature for 1 h. Solvent was
evaporated and
the residue obtained was washed with dry ether and was dried under high vacuum
to give
164 mg (97 %) of desired product as an off-white solid.
Anal. calcd for C21 H27N04 (1.5 HCI): C, 61.2; H, 6.97; N, 3.40. Found: C,
61.62; H,
6.95; N, 3.91.
Example 11:
2-Methyl-propanoyl-galanthamine citric acid salt
To the solution of 2-methyl-propanoyl-galanthamine (150 mg, 0.43 mmol) in
methanol (5
mL), a solution of citric acid in methanol (5 mL) was added slowly with
stirring at room
temperature. The reaction mixture was stirred at room temperature for 1 h.
Solvent was
evaporated and the residue obtained was precipitated from methanol-diethyl
ether and was
dried under high vacuum to give 187 mg (81 %) of desired product as a off-
white solid.
Anal. calcd for C27H35N01 (1.0 H20): C, 57.14; H, 6.57; N, 2.47. Found: C,
57.43; H,
6.48; N, 2.53.
General procedure 3
To a stirred solution of (-)-galanthamine hydrobromide (1.10 mmol) in pyridine
(6 mL) at 0 C
under nitrogen, the corresponding acid chloride (2.2 mmol) was added and the
mixture was stirred
until a TLC showed the reaction to be complete. Then CH2CL2 (10 mL) and water
(10 mL) were
added and stirring was continued for 30 min. The organic layer was separated,
washed with water
(2x10 mL), dried over anhydrous MgSO4 and the solvent removed. The residue was
purified by
flash chromatography giving the product identical in all respects to the
product of example 1.
Example 12:
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
19
Synthesis of R1-pyridinoyl-galantamine
In addition to the examples provided above, the following compounds were
prepared by
the described general procedures:
Table 2:
MF MW Substituent RI
C21H25N04 355,43 cyclopropanecarboxylate
C24H23C12N04 460,3 3,4-dichlorobenzoate
C28H33N04 447,57 4-tert-butylbenzoate
C25H23CIF3N04 493,91 4-chloro-3-(trifluoromethyl)benzoate
C25F-123F3N206 504,46 4-nitro-3-(trifluoromethyl)benzoate
C25H24F3N04 459,47 4-(trifluoromethyl)benzoate
C24H23C12N04 460,36 2,4-dichlorobenzoate
C24H24N206 436,47 4-nitrobenzoate
C24H24CIN04 425,92 3-chlorobenzoate
C25H24F3N04 459,47 3-(trifluoromethyl)benzoate
C24H24N206 436,47 3-nitrobenzoate
C24H23C12N04 460,36 3,5-dichlorobenzoate
C26H30N204 434,54 3-(dimethylamino)benzoate
C25F-1271104 405,50 3-methylbenzoate
C24H24CIN04 425,92 2-chlorobenzoate
C24H23F2N04 427,45 2,4-difluorobenzoate
C24H23C12N04 460,36 2,5-dichlorobenzoate
C24H24FN04 409,46 4-fluorobenzoate
C261-130N204 434,54 4-(dimethylamino)benzoate
C24H26N204 406,49 4-aminobenzoate
C27H32N204 448,57 4-(dimethylamino)-3-methylbenzoate
C25H25N06 435,48 2H-1,3-benzodioxole-5-carboxylate
C261-127N05 433,51 4-acetylbenzoate
C22H23N04S 397,50 thiophene-3-carboxylate
C21 H23N304 381,44 1H-imidazole-5-carboxylate
C21H22N205 382,42 1,3-oxazole-5-carboxylate
C21H22N204S 398,48 1,3-thiazole-5-carboxylate
C21 H22 N204S 398,48 1,3-thiazole-2-carboxylate
C26H27N06 449,51 2-(acetyloxy)benzoate
=
Example 13
Preparation of mouse brain homogenate
The brain is removed from the animal (mouse), shock frozen in liquid nitrogen
and stored
at minus 80 C until use. Before preparing the extract, the frozen brain is
thawed on ice
and the weight is determined. Ice cold buffer (130 mM NaC1, 5 mM KCI, 2.5 mM
CaC12,
1 mM MgC12, 5 mM Glucose, 5 mM HEPES, pH 7.4) is added to the thawed mouse
brain
(1:4, weight to volume, resulting in a 20 % brain homogenate). The tissue is
then
CA 02721007 2012-08-16
=
' WO 2009/127218
PCT/EP2008/002929
homogenized in a potter homogeniser on ice, moving the piston up and down 11
times at
240 rpm. The freshly prepared mouse brain homogenate is divided into aliquots.
5 Example 14
Procedure for measuring the inhibition of brain esterase. Results shown as
figure 1
A modified Ellmann's esterase test is used. Briefly the method relies on the
cleavage of
10 the substrate acetylthiocholine to acetate and thiocholine. The
latter reacts with DTNB
(5,5--Dithiobis-(2-nitro-benzoicacid) to a yellow compound, which can be
quantified
spectrometrically. The incubation buffer contains 51 mmo1/1 sodium phosphate
buffer and
0.05 % TweenTh20, at pH 7.2 and is supplemented with 100 mg/1 DTNB, and 0.2 %
mouse
brain homogenate (prepared as described in Example 13). The compound to be
15 investigated is added to the desired concentration. The mixture is
brought to 37 C and the
reaction is started by addition of 200 M acetylthiocholine. A405 is measured
in is
intervals in a microplate reader for 40 s. The linear parts of the absorption-
time-curves
represent the starting speed of the enzymatic reaction and are used for the
calculation of
the reaction speed. The slope of the curve corresponds to the reaction speed.
The
20 inhibition is expressed as per cent of the non inhibited reaction
according to following
equation:
% Inhibition = 100 * (1 -(Slopeinhibited / Slopenoninhibited)).
Example 15
Procedure for determination of prodrug cleavage in mouse brain homogenate.
To aliquots of mouse brain homogenate as prepared according to Example 13 pro-
galantamine derivatives are added and adjusted to a final concentration of 10
gM of the
prodrug. At the end of the incubation time, 12 AI 0.1 M NaOH and 100 gl
saturated KCI
are added to the 0.1 ml reaction mixture and mixed thoroughly. The remaining
prodrug
and the released galantamine are extracted by 200 I toluene. The toluene
extraction step
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
21
is repeated twice using 150 I toluene and the obtained extracts are pooled,
dried,
dissolved in 50 % Methanol and used for subsequent HPLC analysis.
Example 16
Investigation of the allosteric modulation effect of drug candidates on
nicotinic
acetylcholine receptors (nAChRs) expressed in HEK-293 cells by
electrophysiology.
Results shown as figure 3
Single HEK-293 cells expressing either human a4132, human a3134, or chimeric
chicken a7
(with mouse 5HT3) nAChR were plated on fibronectin-coated cover slips for 3
days before
measurement. The selected nAChR containing cells were placed in the recording
bath,
filled with extracellular buffer (145 mM NaCI, 5 mM KC1, 1 mM MgC12, 2 mM
CaCl2,
10 mM D-glucose, 10 mM HEPES, pH 7.3, approximately 300 mOsm). Patch-clamp
system consisted of an inverted microscope (Zeiss, Germany), computer-
controlled patch-
clamp amplifier with PatchMaster software (HEKA, Germany), tubing perfusion
system
(ALA, USA) together with a U-tube applicator (IMM, Germany) and dual
micromanipulators. The patch pipettes were pulled from fire-polished, 100 mm
long and
1.5 mm width, single borosilicate glass capillaries (WPI, Germany). A
programmable
puller (Sutter, USA) was used to prepare a twin pair of ready for use
pipettes. Each patch
pipette (resistance 4-8 Mf2) was used only once. Pipettes were filled with an
internal
buffer (140 mM CsCI, 11 mM EGTA, 10 mM HEPES, 2 mM MgC12, pH 7.3,
approximately 300 mOsm) and connected to the working electrode. Working and
reference electrodes for experiments were made from daily renewed, freshly
chlorinated
silver wire (40 mm x 0.4 mm) and were connected to a headstage circuit of the
patch-
clamp amplifier. Patching was done using rectangular test pulses with an
amplitude of -1
mV and a duration of 20 ms. Immediately after formation of the gigaseal the
holding
potential of -70 mV was applied to the patch electrode and whole-cell
recordings were
established by using negative pressure pulses. All necessary compensations for
fast and
slow membrane capacitance and serial resistance transients were automatically
set within
the PatchMaster software. Whole-cell currents were evoked by the application
of nicotine
at the EC50 for each appropriate nAChR subtype (a4132 and a3l34 EC50 = 30 p.M,
chimeric
a7 EC50 = 3 M). To evaluate an allosteric potentiating ligand (APL) effect of
selected
compounds on each subtype of nAChR, they were added to stimulating nicotine
solutions
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
22
at the following concentrations: 1, 5, 10, 50, 100, 500, 1,000, 5,000 and
10,000 nM, and
solutions were applied to the cell surface during 500 ms pulses through the U-
tube, and
then corresponding currents, digitized to 10 kHz, were recorded for 10 s.
Consecutive
current stimulations were done with a 2 min interval to avoid nAChR
desensibilisation and
to ensure full exchange of stimulating solutions. The averaged peak amplitudes
of the
currents, measured in the presence of selected compound concentrations, were
compared
with those determined in the absence of compounds (control) and they were
calculated as
% of control. The measurements of an APL effect of particular compound were
repeated
on a minimum of five cells to obtain the mean values +/- SD. Mean values of
the observed
APL effect, which did not exceed 15% were treated as insignificant. To present
a
concentration-dependent APL effect of particular compound, the corresponding %
of
control values +/- SD were plotted against the concentrations used.
Example 17
Pharmacokinetics of pro-galantamine Gln-1062 (3mg/kg) in the mouse, results
shown as
figure 4
STUDY OBJECTIVE
Determination of the pharmacokinetic profiles of Gln-1062 and its cleavage
product
galantamine in blood and brain. Determine the brain-to-blood concentration
ratios of Gin-
1062 and its cleavage product galantamine, and assess the blood-brain barrier
penetration
capacities.
STUDY PLAN
Bioanalysis
Analytical method for estimation of Gln-1062 was evaluated for its linearity,
precision &
accuracy and recovery in SAM blood and brain homogenate using LC/MS/MS.
LC/MS/MS Parameters
The parameters of chromatographic conditions and extraction conditions for the
Gln-1062
and Galantamine analysis were
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
23
Chromatographic parameters:
Column : Phenomenex Synergi, Polar-RP 80 A, C18,
75 x
2.0 mm, 4
Mobile Phase
Mobile Phase Buffer : 40 mM Ammonium Formate, pH 3.5
Aqueous Reservoir (A) : 10% Buffer, 90% Water
Organic Reservoir (B) : 10% Buffer, 90% Acetonitrile
Flow rate : 0.450 mL/min
Gradient Programme:
Gradient
Time (min) %A %B
Curve
0 1 100 0
1.2 1 60 40
3 1 0 100
3.1 1 100 0
5 1 100 0
Divert valve time shedule:
Divert Valve
Time (min)
Waste MS
0 x
1.2 x
4.5 x
Run time : 5.0 min
Column oven temperature : Ambient
Auto sampler temperature : Ambient
Auto sampler Wash :Water:acetonitrile:isopropanol with 0.2%
formic
acid,1:1:1(v/v/v)
Retention time : Gln-1062 : 3.33 0.05 min.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
24
Galantamine : 2.44 0.05 min
Metoprolol : 2.80 0.05 min.
Mass Parameters (API 3200):
Mode : MRM
Polarity : Positive
Ion source : Turbo spray
Analyte : Gln-1062 (Q1
Mass 392.4 ; Q3 Mass 213.2)
Galantamine (Q1 Mass 288.3 ; Q3 Mass 213.1)
ISTD : Metoprolol (Q1 Mass
268.4; Q3 Mass 116.2)
Source/ Gas Parameters:
Curtain gas (CUR) 10
Collision gas
(Collision associated Dissociation) CAD 5
Ion Spray Voltage (IS) 5500 V
Temperature (TEM) 575 C
GS1 55
GS2 45
The ON
Compound Parameters:
Parameter Galantamine Metoprolol Gln-1062
Declustering Potential (V) 45 35 50
Entrance Potential (V) 10 10 10
Collision Cell Entrance Potential
20 20 20.00
(V)
Collision Energy (eV) 32 26 32
Collision Cell Exit Potential (V) 4.5 2 5
Dwell Time (milliSec ) 200 200 200
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
Extraction Procedure:
5 A Preparation of STD, QC and Study samples
To 50IAL of blood/brain homogenate study/spiked sample 1504 of cold
acetonitrile containing Metoprolol (100.03ng/mL) was added
10 Vortexed for 30 seconds.
Centrifuged at 13000 rpm for 10 min at 4 C
100 tL of supernatant diluted with 100 L of milli-Q water
Vortexed and transferred into pre-labeled auto sampler vials.
B Preparation of calibration curve standards for recovery
To 50 L of balnk blood/brain homogenate 1504 of cold acetonitrile
containing Metoprolol (100.03ng/mL) was added
Vortexed for 30 seconds.
Centrifuged at 13000 rpm for 10 min at 4 C
Separate the supernant
Add 2 L of Spiking solution-II to 198 [IL of above supernant and vortex
100 [IL of above mixture diluted with 1004 of milli-Q water
Vortexed and transferred into pre-labeled auto sampler vials
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
26
Method evaluation
This method was evaluated for linearity, precision & accuracy and recovery of
Gln-1062
in SAM blood and brain homogenate.
A. Linearity, precision & accuracy
A single standard curve and six replicates each of three quality control
(QC) levels (18 total QCs) were extracted and analyzed. The linearity of
the calibration curve was determined by a weighed least square regression
analysis.
Acceptance Criteria
i. At least six out of nine standards must have an accuracy of 15% from
nominal, except at the lower limit of quantitation (LLOQ) where 20%
is acceptable.
ii. Two-thirds of the batch QCs and at least half of the QCs at each level
must have a calculated accuracy of 15% from nominal.
iii. Intra-assay Mean Precision and Accuracy
1. Four out of six QCs must be available to determine accuracy and
precision.
2. The intra-assay coefficient of variation (%CV) of each QC level must
not exceed 15% and the accuracy of the mean value for each
validation to be accepted.
Gln-1062 linearity, precision and accuracy in blood and brain
homogenate matrices shown in Table 1 & 2, respectively.
B. Recovery
The recovery of Gln-1062 from the blood and brain homogenate matrices
were also evaluated.
Recovery was determined by quantifying the concentration of the analytes
in extracted matrix QC samples with a standard curve prepared in post-
extract (blank extracts) sample matrix as described in 5.3 B
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
27
Gln-1062 recovery in blood and brain homogenate matrices shown in Table
3 & 4, respectively.
Animal study
Study design
No. of
Dose Dose
Dose Animals Sample time
points
Animal Test item Conc. Volume Dose route
(mg/kg) for each (hr)
(mg/mL) (mL/kg)
time point
Predose, 0.05, 0.10,
Male SAM Gln-1062 i.v, bolus 0.17,0.33,
3 0.2 15 3
25-33 gm (tail vein)
0.50,0.83,1.33,
2.0 and 4.0
Sample collection
Collection of Blood:
Blood samples were collected from the retro-orbital plexus. 0.5 ml of blood
was collected
into a pre-labeled polypropylene micro centrifuge tube containing sodium
citrate as the
anticoagulant, and kept on ice.
Blood was mixed gently with anticoagulant and an aliquot of 500_, of blood
sample
immediately precipitated as described in the section 5.3A. Remaining volume of
blood
sample at each time point frozen on dry ice.
All the blood samples were transferred to analytical department and frozen at
¨ 80 10 C
until analysis.
Collection of Brain:
Immediately after blood withdrawal, brain was perfused with phosphate buffer
saline (pH
7.4), removed and frozen on dry ice.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
28
All the brain samples were transferred to analytical department and frozen at
¨ 80 C until
analysis.
Brain homogenate Preparation:
Brain samples were thawed on ice and weighed. An appropriate volume ice cold
homogenizing media (methanol: water::20:80,v/v) added. On ice, homogenized the
brain
sample with the polytron homogenizer and make up the volume with homogenizing
media
to get 1 gm of brain per 4 mL of homogenate. After homogenizing, immediately
freezed
the brain homogenate samples at -80 C until analysis.
Example 18
Behavioural index for gastro-intestinal side effects in ferrets following
application of
galantamine and several RI -pro-galantamines, respectively. Results shown in
figure 5.
Test system
Fourteen adult male Putoris furo ferrets (Marshall BioResources (North Rose,
USA)),
weighting 750-1000 grams on the day of experimentation were used in the
present study.
In agreement with the sponsor four out of the fourteen animals were included
in two
experimental groups (Tables 3 and 4, ferrets # 1, 2, 3 and 4).
Animal housing
The acclimatization of the animals lasted at least 5 days. At receipt, animals
were
collectively housed in cages at Syncrosome's premises. They had free access to
food and
drinking water ad libitum.
Test item and Reference compound
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
29
During this study, one reference compound (Galantamine) and one Galantos
candidate
compound (GLN979) were tested at two doses each. Both compounds were
administered
I.P. at doses and concentrations which are detailed in table 1.
Details of the different compound shipments are presented in table 2.
Receipt dates November, the
November, the 21th, 2007 November, the 29th, 2007
Compounds 1 1,2007
.
Galantamine 48,0 mg 256.0 mg (One vial)
GLN979 48,0 mg 262.6 mg
2-Hydroxypropy1-13- U.I : (One vial) 7.3 g + 7.3 g (Two
4.7g +P.,' 5.0 g
cyclodextrin vials)
NaCI U.I : (One vial) 3.0 g (One vial)
As requested by the sponsor, the same vehicle (15% 2-Hydroxypropy1-13-
cyclodextrin /
96 mM NaC1) was used for both Galantamine and GLN979 preparation. A detailed
solubilization protocol was sent by mail by Galantos to Syncrosome and
received on
November 5th, 2007.
Test compound (GLN979)
Nature GLN979.
Molar mass U.I.
Administration dose 20 and 40 mg/kg B.W.
Administration route I.P.
Vehicle 15% 2-Hydroxypropyl-3-cyclodextrin / 96 mM NaCl.
Reference compound (Galantamine)
Nature Galantamine
Molar mass U.I.
Administration dose 3 and 20 mg/kg B.W.
Administration route I.P.
Vehicle 15% 2-Hydroxypropy1-13-cyclodextrin / 96 mM NaCl.
I.P. administrations
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
For the 4 experimental groups, the administrations were performed in
unanaesthetized
animals through the I.P. route at To (figure 1). The volumes of administration
for each
group are detailed in table 1.
5 Emesis test
After I.P. administration of the compound solution, the animals were
continuously
observed by a trained technician for four hours. During that period, the
number of
episodes of vomiting (series of retches leading to the expulsion of part of
the gastro-
10 intestinal content) were recorded.
Behavioural observation
During the 4 hours-observation period, several side-effects (salivation,
shivering,
15 respiratory problems and diarrhea) were also observed. For each of these
behaviours, a
scoring method was determined with the sponsor. Depending on its severity,
each
parameter were quantified as:
- "None" (None) = Behaviour not observed.
20 - "Moderate" (Mod.) : Behaviour observed with a low frequency and/or
a
low intensity.
-"Intense" (Int.) = Behaviour observed frequently and/or
continuously
and/or at a high intensity.
25 Inclusion criteria
All the animals receiving I.P. administration of the reference or the test
compound were
included in the study regardless of the pattern of both their emetic responses
and
behavious.
Example 19
Reversal from scopolamine-induced amnesia in mice, results shown as figure 6
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
31
Drug preparation
Gin 1062, Gin 0979 and galanthamine were dissolved in 15% -hydroxypropyl-P-
cyclodextrin in 96 mM NaC1 (isotonic) supplied by the sponsor. Gin 1062 and
Gin 0979
were used in concentrations of 0.01, 0.03, 0.1 and 0.2 mg/ml, which when given
in a
volume of 10 ml/kg result in doses of 0.1, 0.3, 1 and 2 mg/kg i.p.,
respectively.
Galanthamine was used in concentrations of 0.03, 0.1, 0.2 and 0.5 mg/ml, which
when
given in a volume of 10 ml/kg result in doses of 0.3, 1, 2 and 5 mg/kg i.p.,
respectively.
Control animals received 15% -hydroxypropyl-P-cyclodextrin in 96 mM NaC1
injection as
a vehicle.
Nicotine ((¨)-Nicotine hydrogen tartrate salt, Sigma, France), scopolamine (-(-
)scopolamine hydrochloride, Sigma, France) were dissolved in saline (0.9%
NaC1,
Aguettant, France) at the concentration of 0.04 and 0.1 mg/ml, respectively.
They were
administrated at a dosage volume of 10 ml/kg to achieve doses of 0.4 and 1
mg/kg,
respectively.
Test animals
Four to five week old male CD-1 mice (Janvier; Le Genest St Isle ¨ France)
were used for
the study.
They were group-housed (10 mice per cage) and maintained in a room with
controlled
temperature (21-22 C) and a reversed light-dark cycle (12h/12h; lights on:
17:30 ¨ 05:30;
lights off: 05:30 ¨ 17:30) with food and water available ad libitum.
Experimental design
The potential cognitive enhancing property of Gin 1062, Gin 0979 and
galanthamine were
evaluated in scopolamine-treated mice in the T-maze alternation model under
the same
experimental conditions. Both Gin 1062 and Gin 0979 were tested in doses of
0.1, 0.3, 1
and 2 mg,/kg i.p. Galanthamine was tested in doses 0.1, 0.3, 1, 2 and 5 mg/kg
i.p. Nicotine
was tested in a dose of 0.4 mg/kg i.p. All these compounds were administrated
immediately after the injection of 1 mg/kg i.p. scopolamine (20 min prior to
the T-maze
trial) used to induce memory deficit.
Memory performance was assessed by the percentage of spontaneous alternation
in the T-
maze. The number of alternation in saline-injected mice was used as the base
level of
unaltered memory performance.
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
32
Mice were housed 10 per cage. Each mouse in a cage was randomly assigned by a
unique
number (1 to 10) written on the tail with permanent ink.
Gln 1062, Gln 0979 and galanthamine were tested separately in three set of
experiments
with different animals. Each set of experiments was divided in series of daily
experiments
that always comprises at least one representative of each of Saline/vehicle,
Scopolamine/vehicle and Scopolamine/Nicotine (0.4mg/kg) groups.
Measurement
The T-maze apparatus was made of gray Plexiglas with a main stem (55 cm long x
10 cm
wide x 20 cm high) and two arms (30 cm long x 10 cm wide x 20 cm high)
positioned at
90 degree angle relative to the left and right of the main stem. A start box
(15 cm long
x 10 cm wide) was separated from the main stem by a guillotine door.
Horizontal doors
were present to close off specific arms during the force choice alternation
task.
The experimental protocol consists of one single session, which starts with 1
"forced-
choice" trial, followed by 14 "free-choice" trials. In the first "forced-
choice" trial, the
animal is confined 5 s in the start arm and then released while either the
left or right goal
arm is blocked by a horizontal door. After the mouse is released, it will
negotiate the maze
and eventually enter the open goal arm, and return to the start position.
Immediately after
the return of the animal to the start position, the closed goal door is opened
and the animal
is now free to choose between the left and right goal arm ("free choice
trials"). The animal
is considered as entered when it places its four paws in the arm. A session is
terminated
and the animal is removed from the maze as soon as 14 free-choice trials have
been
performed or 10 min have elapsed, whatever event occurs first. The average
duration of a
trial is 6 min.
The apparatus is cleaned between each animal using alcohol (70 ). Urine and
feces are
removed from the maze.
During the trials, animal handling and the visibility of the operator are
minimized as much
as possible.
The percentage of alternation over the 14 free-choice trials was determined
for each
mouse and was used as an index of working memory performance. This percentage
was
defined as entry in a different arm of the T-maze over successive trials
(i.e., left¨right¨
left¨right, etc).
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
33
Statistical analysis
Analysis of variance (ANOVA) was performed on the result data. Fisher's
Protected Least
Significant Difference was used for pairwise comparisons. p value < 0.05 were
considered
significant. The drug induced reversion of scopolamine-induced memory deficit
was
calculated by setting the respective response of the saline/vehicle group as
100% and the
scopolamine/vehicle group as 0% reversion.
In order to determine the ED50 for each drug, the recovery performance was
plotted
following a sigmoidal dose-response model (graphpad software). ED50 was read
from the
curve fitting table and represents the effective dose associated with 50% of
response.
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
34
Table A
moIregro molstructure abbrev.
. 010
GLN-1062Bz-Gal
00
GLN-1081
4-CI-Bz-Gal
SO )
40 Q
GLN-1082 4-1V1e0-Bz-Gal
gh,
=
GLN-1083 4-Me-Bz-Gal
ci
. dif
GLN-1084 V' ) 3,4-C12-Bz-Gal
SUBSTITUTE SHEET (RULE 26)
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
1111
GLN-1085 4-tBu-8z-Gal
1130 0 )
F
GLN-1086 * 3-CF3-4-C1-Bz-Gal
= F
jai F
GLN-1088 4-CF3-9z-Gal
=
= IF
GLNA 089 FfaC'. * 2,4-C12-Bz-Gal
Si 0
GLN-1090.0 40
6- 4-NO2-Bz-Gal
NG )
41; *
=
GLN-1091 Hro * 3-CI-Bz-Gal
SUBSTITUTE SHEET (RULE 26)
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
36
0* = F
GLN-1092 = -) 3-CF3-Bz-Gal
*
itO\ 3-NO2-13z-Gal
4ILir
A" '4
=
GLN-1094 Kr.=
3,6-012-Bz-GI
Npt
it* 4111
GLN-1095 ti,c- = (07,-) 3-Me2N-Bz-Gal
CH,
A. = C4I'
viv
GLN-1096 * 3-M e-Bz-Gal
c
611H,
1011
GLN-1097 *
SUBSTiTUTE SHEET (RULE 26)
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
37
411
.GLN-10982,4-F2-Bz-Gal
Ne'
GLN-1099 =
Ivo = ..õ\
215-C12-Bz-Gal
= 11, F
GLN-1100 hp,c, ====,\ 4-F-Bz-Gal
1,11
,
41111 eel%
GI,N-1101 NG-0 -Of
10-1 CF13 4-NMe2-Bz-GI
CH)
0
9 110
110
GLN-1102 o 4-NH2-Bz-Gal
011,; 40 cti,
nrc"'
GLN-1103 ttc.0 ) 64-1, 3-Me-4-NMe2-Bz-Gal
SUBSTITUTE SHEET (RULE 26)
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
38
0
GLN-1104 .0,643 3,4-0C1-120-6z-Gal
)ti
+
GLN-1105
44\e-Bz-Gal
ti.0 = )
GLN-1113 * 2-MO-Bz-Gai
* )
molregno moistructure abbrev.
GLN-0978 1101 I n-prop-Gal
GLN-0979 H,T j-13ut-oal
SUBSTITUTE SHEET (RULE 26)
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
39
Ke 8;14'
GLN-0992
GLN-0993 * n-Hex-Gal
0H,
GLN-1011 .0 .11.! neo-pent-Gal
)
4,
GLN-1060
H
GLN-1061
FAµKe
GLN-1067 r/S-i-pent-Gal
)
41
SUBSTITUTE SHEET (RULE 26)
CA 02721007 2010-10-08
WO 2009/127218 PCT/EP2008/002929
:1*
GLN-1069
ttc
110
CAS
GI-N-1070 At.
=
7,)
CH,
GLN-1071 *
GLN-1076 **4011t. CyBu-Gal
2-17
JLA
GLN-1077 1-fr 7",)
= 1111,
GLN-1080 PJS-i-pent-Gal
SUBSTITUTE SHEET (RULE 26) .
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
41
,-400
2110 3
GLN-1106 3-Th-Bz-Gal
=
GI-N-1107 1101 2-Th-Bz-Gal
CH,
CI
GLN-1108 Ne" ) 5-C1-2-Th-Bz-Gal
1411,
G LN-1109 o= 5-Im-Bz-Gal
= # =
GLN-1110
Lir ) 5-0A-Bz-Gal
11,1;
a Ir.: \
= =
GLN-1111 ) 5-Th-Bz-GI
SUBSTITUTE SHEET (RULE 26)
CA 02721007 2010-10-08
WO 2009/127218
PCT/EP2008/002929
42
.10
GLN-Q926
111P,,,,, Ni-Gal
1.01
Lc,
GLN-1066 . -0
14.0
SUBSTITUTE SHEET (RULE 26)
